Evidence map›Paper›PMID 41174636›Full record

ArticleBMC public health2025

Global excess tuberculosis mortality during COVID-19: a country-level modeling study of policy and development correlates.

Hamed Karami, Svenn-Erik Mamelund, Alexandra Smirnova, Gerardo Chowell

Abstract read
In one paragraph

Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hamed KaramiDepartment of Mathematics & Statistics, Georgia State University, Atlanta, GA, 30303, USA. hkarami1@student.gsu.edu.
Svenn-Erik MamelundCentre for Research on Pandemics & Society (PANSOC), Oslo Metropolitan University, Oslo, 0130, Norway. masv@oslomet.no.
Alexandra SmirnovaDepartment of Mathematics & Statistics, Georgia State University, Atlanta, GA, 30303, USA.
Gerardo ChowellDepartment of Population Health Sciences, Georgia State University, Atlanta, GA, 30303, USA. gchowell@gsu.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe COVID-19 pandemic disrupted global tuberculosis (TB) control efforts, leading to a surge in TB-related excess mortality, particularly in low- and middle-income countries. Pandemic mitigation measures, such as lockdowns, reallocation of healthcare resources, and reduced access to diagnosis and treatment, contributed to delayed TB care and disease progression. Quantifying this collateral damage is crucial to bolstering health system resilience.

methodsWe estimated country-level excess TB mortality between 2020 and 2023 using annual TB mortality data reported by the World Health Organization (WHO). Our approach leverages the SubEpiPredict toolbox of the ensemble n-sub-epidemic modeling framework, calibrated to pre-pandemic trends (2010-2019) to forecast expected TB deaths in the absence of COVID-19 disruptions. We selected the best-fitting model based on AICc and compared projected and reported deaths to quantify excess mortality, incorporating both normal and Poisson error structures. We further examined associations between excess TB mortality and country-level indicators, including the COVID-19 Stringency Index, Global Health Security (GHS) Index, and Socio-demographic Index (SDI). It is also noteworthy that for each estimate of excess TB deaths, we provide an associated uncertainty.

resultsOur global estimate of 755,876 excess TB deaths (95%CI: 591,099 to 965,015) aligns closely with the WHO estimate of approximately 700,000 excess deaths. Therefore, it can be estimated a global relative excess mortality of 12.8% (95%CI: 11.6% to 14.2%), compared to the WHO estimate of 14.6% (95% CI: 5.9% to 26.7%). We found substantial geographic heterogeneity, with the highest TB excess mortality rates observed in southern Africa, South Asia, and parts of South America. Countries with high GHS or SDI scores did not necessarily exhibit lower excess TB mortality, suggesting that pandemic-specific disruptions and competing priorities may have overridden structural advantages. Weak-to-moderate correlations were observed between excess mortality and pandemic stringency, peaking in 2021 and waning by 2022, possibly reflecting health system adaptation.

conclusionThis study presents a systematic, model-based analysis of global excess TB mortality during the COVID-19 pandemic, emphasizing disparities in pandemic response impacts across countries. The findings highlight the need for integrated and resilient public health systems capable of maintaining essential services amid global crises. Our methodology can support real-time monitoring of collateral effects of pandemics on endemic diseases and guide strategic investments in TB surveillance and care continuity.

Indexed as

COVID-19Global HealthHealth PolicyTuberculosisHumansPandemicsCOVID-19Excess deathsStringency indexTuberculosis

Identifiers

PMID41174636
PMCPMC12577229

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.